NEW YORK, Oct. 12, 2018 (GLOBE NEWSWIRE) --  The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.        

Nevro Corp. (NYSE: NVRO)
Class Period: January 8, 2018 to July 12, 2018
Lead Plaintiff Deadline: October 22, 2018

The complaint alleges that throughout the class period Nevro Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) Nevro had engaged in a fraudulent scheme by using protected confidential and proprietary trade secrets and stolen documents from its competitors to develop and enhance the Company's Senza I and Senza II systems; (2) as a result, Nevro's Senza I and Senza II systems were not "novel" or "proprietary;" (3) these practices caused Nevro to be vulnerable to increased litigation expenses and adverse legal and regulatory action; (4) as a result, Nevro's U.S. sales growth was not sustainable; and (5) consequently, defendants' statements about Nevro's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the NVRO lawsuit: http://www.kleinstocklaw.com/pslra-1/nevro-corp-loss-form?wire=3

LogMeIn, Inc. (NASDAQ: LOGM)
Class Period: March 1, 2017 to July 26, 2018
Lead Plaintiff Deadline: October 19, 2018

The lawsuit alleges that LogMeIn, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) LogMeIn’s business practices had negatively impacted renewal rates for certain of its services; and (2) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Following this news, shares of LogMeIn fell $26.60 to close at $77.85 per share on July 27, 2018.

Get additional information about the LOGM lawsuit: http://www.kleinstocklaw.com/pslra-c/logmein-inc?wire=3

USA Technologies, Inc. (NASDAQGM: USAT)
Class Period: November 9, 2017 to September 11, 2018
Lead Plaintiff Deadline: November 13, 2018

During the class period, USA Technologies, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) USA Technologies’ treatment of contractual arrangements in its financial statements would result in an internal investigation and delay the filing of its annual report for fiscal year 2018; (2) consequently, USA Technologies’ internal controls over financial reporting were weak and deficient; (3) as a result, defendants’ statements about USA Technologies’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Get additional information about the USAT lawsuit: http://www.kleinstocklaw.com/pslra-1/usa-technologies-inc-loss-submission-form?wire=3

AbbVie Inc. (NYSE: ABBV)
Class Period: October 25, 2013 to September 18, 2018
Lead Plaintiff Deadline: November 20, 2018

The complaint alleges that throughout the class period AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, relied in part upon illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would foreseeably lead to heightened scrutiny by State governments and agencies; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Get additional information about the ABBV lawsuit: http://www.kleinstocklaw.com/pslra-1/abbvie-inc-loss-submission-form?wire=3

Alnylam Pharmaceuticals, Inc. (NASDAQGS: ALNY)
Class Period: February 15, 2018 to September 12, 2018
Lead Plaintiff Deadline: November 26, 2018

The complaint alleges that during the class period Alnylam Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (2) as a result, Alnylam’s public statements were materially false and misleading at all relevant times.

Get additional information about the ALNY lawsuit: http://www.kleinstocklaw.com/pslra-1/alnylam-pharmaceuticals-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com